PCM
EXAS

Prelude Capital Management’s Exact Sciences EXAS Stock Holding History

Prelude Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-58,400
Closed -$828K – 1984
2014
Q1 		$828K Buy
+58,400
New +$789K 0.11% 237

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Prelude Capital Management's EXAS Position: Q1 2026 in Review

Prelude Capital Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 131,830 shares — an estimated $13.4M sold.

Prelude Capital Management first reported a position in EXAS in Q2 2014 and held it in 15 quarters. The position peaked at $13.4M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Prelude Capital Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 131,830 Exact Sciences shares in Q1 2026, an estimated $13.4M.
  • Prelude Capital Management first reported a position in Exact Sciences in Q2 2014 and held it in 15 quarters.
  • Prelude Capital Management's Exact Sciences position peaked at $13.4M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.